miscsubjectsAI governance
Evidence review

Semaglutide and Tirzepatide: Human Trial Evidence on Weight Loss and Load Reduction Pathways

bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `semaglutide-tirzepatide`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/semaglutide-tirzepatide

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/semaglutide-tirzepatide/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/semaglutide-tirzepatide/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/semaglutide-tirzepatide/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/semaglutide-tirzepatide/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why Tirzepatide might help you

  1. What keeps failing: Same mechanical overload pattern as other GLP-1 contexts at higher body weight.
  2. What Tirzepatide is studied to do: Studied for GLP-1/GIP weight loss — load reduction on spine and joints.
  3. Therefore for you: If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.

Why Semaglutide might help you

  1. What keeps failing: Weight-related joint and disc overload; metabolic stress on repair capacity.
  2. What Semaglutide is studied to do: Studied for GLP-1-driven weight loss — reduces mechanical load on weight-sensitive tissues.
  3. Therefore for you: If that layer is part of your problem, Semaglutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.

How these fit together

Each compound above targets a different degeneration layer. Together they are a stack — not five copies of the same mechanism.

  • Tirzepatide → metabolic load / body weight
  • Semaglutide → metabolic load / body weight

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 4
  • Claims tagged human evidence: 5
  • Claims tagged preclinical (animal/lab): 0
  • Claims tagged anecdotal: 0
  • Reddit posts catalogued: 0
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 5

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.7 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Tirzepatide Once Weekly for the Treatment of Obesity (source s1)

SURMOUNT-1 phase 3 trial results.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (source s14)

SURMOUNT-5 head-to-head trial.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (source s10)

Semaglutide OA pain trial.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

IMPACT OF TIRZEPATIDE ON MUSCULOSKELETAL PAIN (source s12)

Real-world tirzepatide joint pain study.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Explore this article's relationships

tirzepatide · condition map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
Evidence · 5 sources · swipe →chain 756ec79fb159 · verify chain · provenance
Evidence ledger 5 · tier-ranked · API
humanlow confidence
Tirzepatide produced mean weight loss of 15.0–20.9% at 72 weeks versus 3.1% placebo in SURMOUNT-1 (human trial)
sources: s1
humanlow confidence
Head-to-head SURMOUNT-5: tirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks (human)
sources: s14
humanlow confidence
Semaglutide 2.4 mg improved WOMAC pain by 41.7 points vs 27.5 on placebo in obesity + knee OA (human)
sources: s10
humanlow confidence
Tirzepatide linked to lower risk of joint pain diagnoses (HR 0.89 for low back pain) in real-world data (human)
sources: s12
humanlow confidence
Real-world weight loss averages ~8.7% at one year, lower than trials due to adherence and dosing (human)
sources: s4
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-30 00:18
Semaglutide and Tirzepatide: Human Trial Evidence on Weight Loss and Load Reduction Pathways · 5 claims · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: Semaglutide for Tirzepatide
Slug: semaglutide-tirzepatide
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"dual_compound","condition":null,"condition_key":null,"primary_peptide":null,"peptides_in_scope":[{"id":"tirzepatide","name":"Tirzepatide"},{"id":"semaglutide","name":"Semaglutide"}],"drugs_in_scope":[],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_
it output
{
  "slug": "semaglutide-tirzepatide",
  "title": "Semaglutide and Tirzepatide: Human Trial Evidence on Weight Loss and Load Reduction Pathways",
  "body": "## What's breaking down\n\nHigher body weight creates ongoing mechanical overload on weight-bearing tissues. Each extra pound of body mass transmits roughly four pounds of compressive force through the lumbar spine during upright activity. Over time this pattern can accelerate disc height loss, joint surface wear, and connective tissue strain. Metabolic stress from excess adiposity may further slow natural repair processes in these tissues. Both semaglutide and tirzepatide are studied primarily for their effects on body weight; any downstream tissue benefit would flow from reduced load rather than direct repair signaling.\n\n## Why Tirzepatide might help you\n\n1. What keeps failing: The same mechanical overload pattern seen in other GLP-1 contexts, but potentially amplified at higher starting body weight.\n2. What Tirzepatide is studied to do: Dual GLP-1/GIP agonism produces substantial weight reduction in human trials.\n3. Therefore for you: If excess body weight contributes to your tissue overload, tirzepatide is discussed because it targets the load-reduction layer — not because it masks symptoms.\n\n## Why Semaglutide might help you\n\n1. What keeps failing: Weight-related overload on joints and discs plus metabolic st
4565342f8a9c096b
Machine verification: /api/articles/semaglutide-tirzepatide/contributions
Ask this article · 7 suggested prompts

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "Tirzepatide produced mean weight loss of 15.0–20.9% at 72 weeks versus 3.1% placebo in SURMOUNT-1 (human trial)"?
ask semaglutide-tirzepatide claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "Head-to-head SURMOUNT-5: tirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks (human)"?
ask semaglutide-tirzepatide claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "Semaglutide 2.4 mg improved WOMAC pain by 41.7 points vs 27.5 on placebo in obesity + knee OA (human)"?
ask semaglutide-tirzepatide claim c3 · paste includes §SELF
What does the ledger say about this (human tier): "Tirzepatide linked to lower risk of joint pain diagnoses (HR 0.89 for low back pain) in real-world data (human)"?
ask semaglutide-tirzepatide claim c4 · paste includes §SELF
What does the ledger say about this (human tier): "Real-world weight loss averages ~8.7% at one year, lower than trials due to adherence and dosing (human)"?
ask semaglutide-tirzepatide claim c5 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about Semaglutide and Tirzepatide: Human Trial Evidence on Weight Loss and Load Reduction Pathways — and what would you need me to tell you first?
ask semaglutide-tirzepatide condition gaps · paste includes §SELF
What good and bad outcomes are documented for Semaglutide and Tirzepatide: Human Trial Evidence on Weight Loss and Load Reduction Pathways (studies vs anecdotes)?
ask semaglutide-tirzepatide good bad experiences · paste includes §SELF
semaglutide-tirzepatide · posted 2026-06-29 · updated 2026-07-17 · 1 prior revision · grok/grok-4.3
Ledger API & provenance
Provenance · 2 model passes · 21390 tokens · $0 · 2 models
chain head d71ea45d6bd68224
write grok/grok-4.3 · 2026-06-30 00:18 · 21390 tok · ad6f25ff2c7f
voxel_divide owner · 2026-07-17 02:41 · tokens unrecorded · d71ea45d6bd6
verify chain →
Live ledger · 28 payloads · 1 turn
recent activity · inspect
JCI_TRAFFIC jci · HTTP 200 · 2026-07-28 12:45
JCI_TRAFFIC jci · HTTP 200 · 2026-07-28 12:45
JCI_CLASSIFY jci · HTTP 200 · 2026-07-28 12:45
JCI_TRAFFIC jci · HTTP 200 · 2026-07-28 12:43
JCI_TRAFFIC jci · HTTP 200 · 2026-07-28 12:35
JCI_TRAFFIC jci · HTTP 200 · 2026-07-28 11:49
view full ledger & cards →
REST + ledger
read GET /api/articles/semaglutide-tirzepatide · GET /api/articles/semaglutide-tirzepatide?format=post (the editable body)
create/replace POST /api/articles/semaglutide-tirzepatide · PUT /api/articles/semaglutide-tirzepatide (replace, keeps revision) · PATCH /api/articles/semaglutide-tirzepatide (merge)
delete DELETE /api/articles/semaglutide-tirzepatide
writes need header x-terminal-key
LLM bundle GET /api/articles/semaglutide-tirzepatide/bundle?format=markdown — body + claims + sources + provenance + manifest
post claim POST /api/protocol/claim · iMessage claim semaglutide-tirzepatide|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →